Over the last few decades, holmium (Ho) has been investigated for its application in laser surgery, magnetic resonance imaging, and internal and topical radionuclide therapy. Ho has a 100% natural abundance of holmium-165, which is a stable nuclide that can undergo a process called neutron-activation to generate radioactive holmium-166 (¹⁶⁶Ho). ¹⁶⁶Ho emits β^–particles and γ photons, with a half-life of 26.8 h; β^–particles can damage a cancer cell’s DNA, while γ photons allow for ¹⁶⁶Ho to be imaged in vivo and easily quantitated prior to, or during, dosing. This article gives a thorough account of the work being done around the world on ¹⁶⁶Ho for use as an internal or topical radionuclide therapy against cancer. Our research group and others have generated compelling data that support the use of ¹⁶⁶Ho as a radiotherapeutic in the clinic, especially since pharmaceutical formulations can be made while non-radioactive (Ho) and then made radioactive (¹⁶⁶Ho) just prior to use.

在过去的几十年中，人们一直在研究laser（Ho）在激光手术，磁共振成像以及内部和局部放射性核素治疗中的应用。Ho具有165％的100％自然丰度，natural是一种稳定的核素，可以经历称为中子活化的过程，以生成放射性166（¹⁶⁶ Ho）。¹⁶⁶何个发射β ^-粒子和γ光子，26.8小时的半衰期; β ^-颗粒可以破坏癌细胞的DNA，而γ光子允许¹⁶⁶何要被成像在体内和容易定量之前或期间，剂量。本文全面介绍了^166年世界各地正在进行的工作Ho用作癌症的内部或局部放射性核素治疗。我们的研究小组和其他研究人员已经获得了令人信服的数据，这些数据支持在临床^上将166 Ho用作放射治疗剂，尤其是因为可以在非放射性（Ho）时制备药物制剂，然后在使用前将其制成放射性（¹⁶⁶ Ho）。